Cellular Biomedicine Group (NASDAQ:CBMG) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01), MarketWatch Earnings reports. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%.
Shares of NASDAQ:CBMG traded up $0.08 on Thursday, hitting $17.09. 8,907 shares of the company were exchanged, compared to its average volume of 34,517. Cellular Biomedicine Group has a one year low of $12.04 and a one year high of $25.00. The company has a market cap of $312.98 million, a price-to-earnings ratio of -9.60 and a beta of 2.91.
Several research analysts recently commented on the stock. BidaskClub downgraded shares of Cellular Biomedicine Group from a “hold” rating to a “sell” rating in a report on Friday, October 26th. Robert W. Baird assumed coverage on shares of Cellular Biomedicine Group in a report on Wednesday, February 6th. They issued an “outperform” rating and a $26.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.67.
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
See Also: How to Invest in an Index Fund
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.